HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L'Oreal Seeks Monograph Inclusion Of Next-Gen Mexoryl UV Filter

This article was originally published in The Rose Sheet

Executive Summary

L'Oreal has filed to have the second of its organic UV filters - drometrizole trisiloxane, marketed as Mexoryl XL - added to FDA's monograph for over-the-counter sunscreen drug products

You may also be interested in...



Most U.S. Sunscreens Not So Hot, Reflecting FDA Failures – EWG

Sunscreen products earned low marks in EWG’s 2013 guide because FDA’s regulation of the category is not rigorous enough, the group says. But the Personal Care Products Council cautions that consumers may get the wrong message from EWG and choose to not use sunscreen.

Most U.S. Sunscreens Not So Hot, Reflecting FDA Failures – EWG

The majority of sunscreen products in the U.S. still don’t meet the Environmental Working Group’s standards. Just 25% of the sunscreen products evaluated for the group’s 2013 Sunscreen Guide pass muster, underscoring the need for a finalized sunscreen monograph and ingredient options for sunscreen formulators on par with those in Europe, EWG says.

EWG’s Sunscreen Recommendations Up From 2010, But Health Concerns Remain

With FDA’s final sunscreen monograph reportedly around the corner, a greater percentage of sunscreens garnered the Environmental Working Group’s approval this year than in past market surveys, but the group still has concerns about sunscreen regulation and ingredient safety.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel